Literature DB >> 11160703

Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

I Hötzel1, W P Cheevers.   

Abstract

We recently described a sequence similarity between the small ruminant lentivirus surface unit glycoprotein (SU) gp135 and the second conserved region (C2) of the primate lentivirus gp120 which indicates a structural similarity between gp135 and the inner proximal domain of the human immunodeficiency virus type 1 gp120 (I. Hötzel and W. P. Cheevers, Virus Res. 69:47-54, 2000). Here we found that the seven-amino-acid sequence of the gp120 strand beta 25 in the C5 region, which is also part of the inner proximal domain, was conserved in the SU of all lentiviruses in similar or identical positions relative to the carboxy terminus of SU. Sequences conforming to the gp135-gp120 consensus for beta-strand 5 in the C2 region, which is antiparallel to beta 25, were then sought in the SU of other lentiviruses and retroviruses. Except for the feline immunodeficiency virus, sequences similar to the gp120-gp135 consensus for beta 5 and part of the preceding strand beta 4 were present in the SU of all lentiviruses. This motif was highly conserved among strains of each lentivirus and included a strictly conserved cysteine residue in beta 4. In addition, the beta 4/beta 5 consensus motif was also present in the conserved carboxy-terminal region of all type A and B retroviral envelope surface glycoproteins analyzed. Thus, the antiparallel beta-strands 5 and 25 of gp120 form an SU surface highly conserved among the lentiviruses and at least partially conserved in the type A and B retroviral envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160703      PMCID: PMC115150          DOI: 10.1128/JVI.75.4.2014-2018.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Sequence similarity between the envelope surface unit (SU) glycoproteins of primate and small ruminant lentiviruses.

Authors:  I Hötzel; W P Cheevers
Journal:  Virus Res       Date:  2000-08       Impact factor: 3.303

3.  Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.

Authors:  C Leroux; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Complete sequence of enzootic nasal tumor virus, a retrovirus associated with transmissible intranasal tumors of sheep.

Authors:  C Cousens; E Minguijon; R G Dalziel; A Ortin; M Garcia; J Park; L Gonzalez; J M Sharp; M de las Heras
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoprotein.

Authors:  S Valas; C Benoit; C Baudry; G Perrin; R Z Mamoun
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  North American and French caprine arthritis-encephalitis viruses emerge from ovine maedi-visna viruses.

Authors:  S Valas; C Benoit; C Guionaud; G Perrin; R Z Mamoun
Journal:  Virology       Date:  1997-10-27       Impact factor: 3.616

7.  Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype.

Authors:  R Skraban; S Matthíasdóttir; S Torsteinsdóttir; G Agnarsdóttir; B Gudmundsson; G Georgsson; R H Meloen; O S Andrésson; K A Staskus; H Thormar; V Andrésdóttir
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; S Saragosti; H J Fleury; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  5 in total

1.  Domain Organization of Lentiviral and Betaretroviral Surface Envelope Glycoproteins Modeled with AlphaFold.

Authors:  Isidro Hötzel
Journal:  J Virol       Date:  2021-10-27       Impact factor: 6.549

2.  Deep-Time Structural Evolution of Retroviral and Filoviral Surface Envelope Proteins.

Authors:  Isidro Hötzel
Journal:  J Virol       Date:  2022-03-23       Impact factor: 6.549

3.  Caprine arthritis-encephalitis virus envelope surface glycoprotein regions interacting with the transmembrane glycoprotein: structural and functional parallels with human immunodeficiency virus type 1 gp120.

Authors:  Isidro Hötzel; William P Cheevers
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses.

Authors:  J D Trujillo; N M Kumpula-McWhirter; K J Hötzel; M Gonzalez; W P Cheevers
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Authors:  Lianxing Liu; Yanmin Wan; Lan Wu; Jianping Sun; Huiguang Li; Haishan Li; Liying Ma; Yiming Shao
Journal:  Retrovirology       Date:  2010-09-01       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.